Navigation Links
Declining fortunes of Yellowstone's migratory elk
Date:6/28/2013

In the late spring, the 4000 elk of the Clarks Fork herd leave crowded winter grounds near Cody, Wyoming, following the greening grass into the highlands of the Absaroka Mountains, where they spend the summer growing fat on vegetation fed by snowmelt. It's a short trip (40-60 kilometers) by migratory standards, and by modern standards, uncommonly free of roads, fences, metropolitan areas, and other human-built barriers. But it crosses an important human boundary: the border into Yellowstone National Park.

The costs of migrating to the high green pastures have lately outstripped the benefits, according to a research report in the June issue of the Ecological Society of America's journal Ecology, published last week. Arthur Middleton and colleagues at the University of Wyoming, the Wyoming Game and Fish Department, and the U.S. Geological Survey reported that the migratory Clarks Fork herd has been returning to winter grounds with fewer and fewer calves over the last few decades. Herds that remain in the vicinity of Cody year-round have more surviving calves. Middleton et al. attribute the change in migration fortunes to climate change and a resurgence within the park of predators that hunt newborn elk calves.

In a Forum edited by Marco Festa-Bianchet, of the Universit de Sherbrooke, Qubec, five working groups of ecologists commented on the data, praising Middleton and colleagues' work, but, in some cases, challenging their interpretation. Middleton and colleagues addressed the commentary in a rebuttal.

Historically, migratory hoofed beasts like elk have outnumbered sedentary members of their species by as much as an order of magnitude. John Fryxell, a Forum contributor, wrote a classic paper on this effect in the American Naturalist in 1988. Mig
'/>"/>

Contact: Liza Lester
llester@esa.org
202-833-8773 x211
Ecological Society of America
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Bioeconomy as a solution for South Australias declining forest industry
2. Declining air pollution levels continue to improve life expectancy in US
3. Environmental change impacts on migratory shorebirds differ for males and females
4. New research on migratory behavior of oceanic whitetip sharks can help shape conservation strategies
5. Migratory moths profit from their journey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2015)... May 14, 2015 Research and Markets ... "Fingerprint Sensors Market in Smart Mobile Devices " ... believes that 2014 was a watershed year for fingerprint ... of ,Apple Pay,. Apple gave fingerprint sensors a raison ... service. Fingerprint sensors are a must-have feature in flagship ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... of an unknown perpetrator who has committed a crime will ... MC scientists, in collaboration with their Polish colleagues, have discovered ... color. Their findings will be published today in the Springer ... that on the basis of DNA information it is possible ...
... (PHILADELPHIA) An international team of researchers led ... Penn Medicine,s Institute for Translational Medicine and Therapeutics, ... Paris-based Fondation Leducq to study the molecular genetics ... Mechanisms of Novel Genes Associated with Plasma Lipids ...
... Many young people who,ve just learned that they have cancer ... lives could rob them of their ability ever to have ... population: Of the 1.5 million people diagnosed with cancer in ... The good news, according to an article in ...
Cached Biology News:Hair color of unknown offenders is no longer a secret 2Penn Medicine researcher receives $6 million grant for cardiovascular disease study 2Advancements in fertility preservation provide oncology patients new options 2Advancements in fertility preservation provide oncology patients new options 3
(Date:6/1/2015)... June 1, 2015  Fennec Pharmaceuticals, Inc. (TSX: ... interim results from a poster presented today entitled, ... randomised phase III trial of the efficacy of ... receiving cisplatin (Cis) monotherapy for standard risk hepatoblastoma ... Society of Clinical Oncology (ASCO) 2015 Annual Meeting ...
(Date:6/1/2015)... , ROCHESTER, Minn. and ... 2015 Baxter Ventures, the venture arm of ... Clinic and Velocity Pharmaceutical Development, LLC ("VPD") today announced ... a unique collaboration model initiated by Baxter Ventures to ... in the areas of immunology, hematology, and oncology. Following ...
(Date:6/1/2015)... Esperance Pharmaceuticals Inc. today reported positive results ... in ovarian cancer patients resistant to paclitaxel. EP-100 is ... cancer cells that overexpress luteinizing hormone-releasing hormone (LHRH) receptors ... wide range of cancers. Results of ... were presented at the 2015 ASCO Annual Meeting ...
(Date:6/1/2015)... 2015 Research and Markets ( ... the "2015 Strategies in European Immunoprotein ... offering. This new 273-page report ... market, including emerging tests, technologies, instrumentation, sales ... leading suppliers. Companies Mentioned: ...
Breaking Biology Technology:Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 2Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting 3
... - CEO Michael V. Novinski to Discuss Plans ... CEDAR KNOLLS, N.J., Jan. 31 Emisphere,Technologies, Inc. ... will host a,teleconference on Thursday, February 7, at ... V. Novinski will discuss the company,s,emerging business strategy. ...
... Names Board of Directors, SAN DIEGO, Jan. ... developing therapeutics for the,treatment of Alzheimer,s disease, announced ... Series A round of financing. The financing was ... Alta Partners. Additional,investors included AgeChem Venture Fund, and ...
... Foundation Continues Research Initiatives in Search of a Cure and Therapies ... ... N.J., Jan. 31 The Christopher and Dana,Reeve Foundation (CDRF), which ... improving the quality of life for people,living with paralysis through grants, ...
Cached Biology Technology:Emisphere to Host Business Strategy Conference Call on February 7 2Emisphere to Host Business Strategy Conference Call on February 7 3Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 2Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimer's Treatments 3Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 2Christopher and Dana Reeve Foundation Awards Nearly $2 Million in Individual Research Grants 3
...
5 minutes from gel band to purified DNA...
Sterile concentration of Dithiothreitol (DTT) solution in phosphate buffer (pH 7.0). Dilute contents in one vial (10- fold) to 100 ml. For use in liquefying sputum samples....
...
Biology Products: